PTC Therapeutics Inc (PTCT)
28.45
+2.96
(+11.61%)
USD |
NASDAQ |
Apr 26, 10:36
PTC Therapeutics Free Cash Flow: -279.04M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -279.04M |
| September 30, 2023 | -343.25M |
| June 30, 2023 | -363.59M |
| March 31, 2023 | -403.42M |
| December 31, 2022 | -509.11M |
| September 30, 2022 | -409.03M |
| June 30, 2022 | -421.96M |
| March 31, 2022 | -395.50M |
| December 31, 2021 | -336.66M |
| September 30, 2021 | -327.02M |
| June 30, 2021 | -249.86M |
| March 31, 2021 | -271.06M |
| December 31, 2020 | -250.05M |
| September 30, 2020 | -193.10M |
| June 30, 2020 | -221.28M |
| March 31, 2020 | -197.82M |
| December 31, 2019 | -144.08M |
| September 30, 2019 | -142.07M |
| June 30, 2019 | -115.87M |
| March 31, 2019 | -72.09M |
| December 31, 2018 | -43.17M |
| September 30, 2018 | 0.355M |
| June 30, 2018 | -91.23M |
| Date | Value |
|---|---|
| March 31, 2018 | -77.56M |
| December 31, 2017 | -90.33M |
| September 30, 2017 | -124.13M |
| June 30, 2017 | -55.06M |
| March 31, 2017 | -92.62M |
| December 31, 2016 | -105.34M |
| September 30, 2016 | -122.08M |
| June 30, 2016 | -126.08M |
| March 31, 2016 | -131.60M |
| December 31, 2015 | -127.06M |
| September 30, 2015 | -107.27M |
| June 30, 2015 | -96.28M |
| March 31, 2015 | -85.62M |
| December 31, 2014 | -61.94M |
| September 30, 2014 | -65.27M |
| June 30, 2014 | -53.47M |
| March 31, 2014 | -53.52M |
| December 31, 2013 | -47.77M |
| September 30, 2013 | -43.98M |
| June 30, 2013 | -44.62M |
| March 31, 2013 | -39.25M |
| December 31, 2012 | -48.12M |
Free Cash Flow Range, Past 5 Years
-509.11M
Minimum
Dec 2022
-115.87M
Maximum
Jun 2019
-293.36M
Average
-279.04M
Median
Dec 2023
Free Cash Flow Benchmarks
| Sarepta Therapeutics Inc | -588.34M |
| Catalyst Pharmaceuticals Inc | 61.86M |
| Pfizer Inc | 4.793B |
| Geron Corp | -168.57M |
| Perspective Therapeutics Inc | -37.98M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -100.29M |
| Cash from Investing (Quarterly) | -94.42M |
| Cash from Financing (Quarterly) | 620.48M |
| Free Cash Flow Per Share (Quarterly) | -1.705 |
| Free Cash Flow to Equity (Quarterly) | -1.654B |
| Free Cash Flow to Firm (Quarterly) | -84.83M |
| Free Cash Flow Yield | -13.11% |